December 10, 2021
Estimating 10-Year Progression-Free Survival in Hodgkin Lymphoma
Researchers across the United States recently used an oncology simulation model to estimate the survival of patients with classical Hodgkin lymphoma (cHL) for 10 years after treatment. Specifically, the study sought to estimate the future number of patients with stage III or IV cHL who are alive and progression-free over 10 years for patients who...
Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma
A new retrospective analysis of pediatric patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL), published in Blood, will be presented at the 2021 ASH Annual Meeting & Exposition. While there is a phase 3 randomized controlled trial supporting the use of brentuximab vedotin (BV) in adults with R/R HL after receiving autologous stem cell transplantation (ASCT),...
Exciting New Data from McKesson Collaboration Shared at ASH 2021
Collaboration between US Oncology Research, The US Oncology Network (The Network), and Ontada™ from McKesson resulted in more than 30 studies being submitted by the group for the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. The studies delve into various areas of blood disorders and related treatments, including different types of lymphomas...
Presentations of Multiple Studies on Rylaze and Vyxeos at ASH 2021
As part of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Jazz Pharmaceuticals participated in 16 new studies that will be shared at the meeting. In a press release, they highlighted particularly exciting studies related to their medications, such as Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) and Vyxeos® (daunorubicin and cytarabine), being used...
New Data on Epcoritamab Presented by Genmab at ASH 2021
In anticipation of the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, Genmab A/S shared through a press release some of the highlights of the over 20 abstracts involving their medicines and drug development platforms, particularly with their work with epcoritamab (DuoBody®-CD3xCD20). They also announced their plan to host a Virtual R&D Update...
Numerous New Studies and Expert Event from Roche at ASH 2021
More than 90 abstracts feature the incorporation of Roche medicines at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition this year. In a press release from the company, Roche detailed the data of studies on multiple types of blood diseases, including different lymphomas, and shared more details about an event they are...
ASH 2021: Multiple Studies Highlight New Data on ADCETRIS®
At the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, taking place in December 2021, almost 20 abstracts will be shared about ADCETRIS® (brentuximab vedotin), a possible therapy to combine with others for advanced stage classical Hodgkin lymphoma (cHL). In a press release, Seagen Inc. recently announced the planned presentations at ASH 2021...
Biotech Company Previews Key Data and Findings for ASH 2021
In preparation for presenting at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, biotechnology company Amgen recently shared a preview of the data of a follow-up to a phase 3 trial focused on pediatric patients and the initial safety and efficacy results of the addition of KYPROLIS to the treatment for patients...
Highlights and Notable Events for ASH 2021
The American Society of Hematology (ASH) is returning partially in person for their annual meeting. Held virtually and in Atlanta, GA, the meeting and exposition is poised to continue the connection of healthcare professionals and evolving research in hematology, including key sessions on how COVID-19 impacts the field. At a recent pre-meeting press briefing, representatives...